Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EVALUATION ON SERUM 2'-5' OLIGOADENYLATE SYNTHETASE (2'-5' OLIGOAS) AND BETA-2-MICROGLOBULIN (B2M) IN PATIENTS WITH NODAL METASTASES FROM CUTANEOUS MALIGNANT-MELANOMA TREATED WITH RIFN-ALPHA-2A
Autore:
MARTINETTI A; SEREGNI E; BELLI F; MAZZOCCHI A; AGRESTI R; CASCINELLI N; GRECO M; BOMBARDIERI E;
Indirizzi:
IST NAZL STUDIO & CURA TUMORI,DIV NUCL MED,VIA VENEZIAN 1 I-20133 MILAN ITALY IST NAZL STUDIO & CURA TUMORI,DIV NUCL MED I-20133 MILAN ITALY IST NAZL STUDIO & CURA TUMORI,DEPT SURG ONCOL B I-20133 MILAN ITALY IST NAZL STUDIO & CURA TUMORI,DIV EXPT ONCOL D I-20133 MILAN ITALY
Titolo Testata:
Anticancer research
fascicolo: 3B, volume: 18, anno: 1998,
pagine: 2027 - 2030
SICI:
0250-7005(1998)18:3B<2027:EOS2OS>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
INTERFERON THERAPY; CLINICAL-RESPONSE; ONCOLOGY GROUP; ALPHA; CHEMOTHERAPY; INDUCTION; LEUKEMIA; INVIVO; SYSTEM;
Keywords:
MELANOMA; ADJUVANT IMMUNOTHERAPY; RIFN-ALPHA-2A; BIOLOGICAL MARKERS; BETA(2) MICROGLOBULIN; 2'-5' OLIGOADENYLATE SYNTHETASE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
28
Recensione:
Indirizzi per estratti:
Citazione:
A. Martinetti et al., "EVALUATION ON SERUM 2'-5' OLIGOADENYLATE SYNTHETASE (2'-5' OLIGOAS) AND BETA-2-MICROGLOBULIN (B2M) IN PATIENTS WITH NODAL METASTASES FROM CUTANEOUS MALIGNANT-MELANOMA TREATED WITH RIFN-ALPHA-2A", Anticancer research, 18(3B), 1998, pp. 2027-2030

Abstract

IFN-alpha is a promising adjuvant agent in patients with regional melanomatous metastases (stage IIIB). The aim of this study was to verifywhether serum evaluation of the interferon induced proteins 2'-5' oligoAS and B2M can pl edict the clinical response to rIFN-alpha 2A therapy. Patients and Methods: Forty-two patients who had undergone radicaldissection of nodal metastases were evaluated All patients received adjuvant rIFN-alpha 2A (3 million units s.c. three times weekly) for. 3years or until progression. The patients were followed for a median period of 43 months (range 19-46). During follow-up 22 of the 42 patients had disease progression. In all patients blood samples were obtained before starting adjuvant therapy and after. 1 and 6 months of therapy with rIFN-alpha 2A. 2'-5' oligoAS and B2M were measured by radioimmunoassay. Results: During the first month of adjuvant therapy with rlFN-alpha 2A the serum levels of 2'-5' oligoAS increased 10-fold, and this trend was maintained in the following 6 months. Similar results wereobtained for B2M serum levels. However, we did not find any significant difference in AS and B2M serum levels between responders and nonresponders. Conclusion. Our results, therefore, indicate that AS and B2M are markers of the biological activity of administered IFN but that they have little efficacy in predicting the clinical outcome of the treated patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 09:58:36